A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 months. Amyloid PET scans will be conducted at screening, 9, and 18 months in Part 1. Participants who are at or below 11 CL at screening or reach complete amyloid plaque clearance as measured by florbetapir F18 PET (defined as ≤11 CL) at 9 months will initiate Part 2. Participants who are ≤11 CL at screening may delay their entry into Part 2 for up to 6 months at the discretion of the Investigator. All remaining participants will start Part 2 after completing 18 months (76 weeks) in Part 1 independent of amyloid results. Non-carriers will receive placebo in both Parts 1 and 2.
In Part 2, study participants who are mutation carriers will be randomized 1:1:1:1 in a full factorial design to receive either RG6289 + placebo-donanemab (RG6289 alone group), donanemab + placebo-RG6289 (donanemab alone group), the combination of RG6289 and donanemab (combination group), or placebo-RG6289 and placebo-donanemab (placebo group). All non-carriers will be assigned to the placebo group. CDR-GS at the end of Part 1 and the amyloid level using the last completed amyloid PET scan in Part 1 will be used for stratification. All study participants will participate in a double-dummy design for the duration of Part 2 receiving both an intravenous (IV) infusion at the required interval for the donanemab or matching placebo as well as a daily oral treatment of RG6289 or matching placebo.
An exploratory outcome of Part 1 is a comparison of the amyloid clearance between this ADAD cohort and historical controls using propensity score matching. The primary outcome in Part 2 is change from the start of Part 2 through the end of Part 2 in brain amyloid load in PSEN1 E280A mutation carriers as measured by amyloid PET imaging. Other endpoints will include fluid and imaging biomarkers and measures of cognition and functioning. The maximum study duration for any individual participant will be 3 years, not including the screening or follow-up periods

Start Date15 Jan 2026

Sponsor / Collaborator

Banner Health

[+2]

NCT06911944

/ Not yet recruitingPhase 4IIT

A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome

The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 years old and will be in the study for 12 months. Participants will then stay in the study for an additional 12 months in an long-term extension where all participants will receive donanemab. Participants who had a reduction in amyloid (measured by amyloid brain scan) by the end of the first 12 months will receive placebo for the long-term extension, while participants who did not have an amyloid reduction will receive study donanemab for the long-term extension. Everyone (participants and study staff) will remain blinded to treatment for the duration of the study.
Participants will:
* Have intravenous (IV) infusions of donanemab (or placebo) every 4 weeks
* Visit the clinic once every other month for checkups and tests. These tests will include brain scans (magnetic resonance imaging [MRI] and positron emission tomography [PET] ), blood draws and memory tests.
* Have a study partner who who can provide information about the participant and can join participant for some of the study visits.

Start Date01 Dec 2025

Sponsor / Collaborator

University of Southern California

[+3]

NCT06566170

/ RecruitingNot Applicable

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

Start Date07 Oct 2024

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Donanemab-AZBT

100 Translational Medicine associated with Donanemab-AZBT

100 Patents (Medical) associated with Donanemab-AZBT

243

Literatures (Medical) associated with Donanemab-AZBT

01 Feb 2026·Neural Regeneration Research

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Article

Author: Guo, Wanshu ; Sha, Sha ; Ren, Lina ; Qu, Le ; Li, Ying ; Cao, Yunpeng ; Xing, Xiaona ; Wang, Yan

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.

01 Nov 2025·JPAD-Journal of Prevention of Alzheimers Disease

Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries

Review

Author: Shea, Yat Fung ; Tan, Lolita Stephanie ; Park, Kee Hyung ; Prusty, Vinay ; Hsu, Jung-Lung ; Panegyres, Peter K ; Eom, Young In ; Huang, Yao Hsien

Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. Reviews of AD prevalence and diagnostic and treatment patterns typically focus on global or western populations, but the situation in Asia, Australasia, and Pacific Nations (AAPN) countries is less clear. We performed a narrative review of literature for AD in several AAPN countries, focusing on patients with MCI or mild dementia who may benefit from early treatment. Published information regarding AD incidence and prevalence and current practice in AAPN countries is limited and the nature of available information differs between countries. However, AAPN countries include some of the most rapidly aging populations and show the associated increasing trend of all-cause dementia prevalence observed globally. Although lecanemab and donanemab are now approved for AD with MCI and mild dementia in several AAPN countries, the most appropriate diagnostic pathway for patients with MCI and early AD is not established. Even though the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment. Guidelines and national policies also need updating to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD.

01 Nov 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Mapping the evolving landscape of lecanemab research in Alzheimer's Disease: A bibliometric analysis

Article

Author: Xu, Dingwen ; Shen, Jiaxing ; Ma, Ruijia ; Yang, Zhe ; Zhao, Xu

BACKGROUND:

Lecanemab, a monoclonal antibody that targets amyloid-beta aggregates, has emerged as a promising therapeutic for Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by cognitive decline and amyloid pathology. Research on the use of lecanemab in treating AD has increased; however, no relevant bibliometric analyses have been conducted. To address this gap, this study employed bibliometric methods to search for the relevant literature and analyze research trends investigating AD and lecanemab.

METHODS:

We performed a literature search of the Web of Science core database for studies investigating AD and lecanemab, published from database inception up to April 3rd, 2025. After rigorous screening, Excel, VOSviewer, and CiteSpace were used to perform a bibliometric analysis of publications, citations, and collaboration networks among countries, institutions, and authors, along with cluster and burst analyses of keywords. Coremine was used for text mining entries significantly related to AD and lecanemab.

RESULTS:

The number of studies published on AD and lecanemab has increased annually. The countries with the highest publication output were the United States, the United Kingdom, and China. The leading institutions that produced the most articles were Eisai Inc. (Bunkyo City, Tokyo, Japan), Uppsala University (Uppsala, Sweden), and Harvard Medical School (Boston, MA, USA). The top three authors were Lars Lannfelt, Shobha Dhadda, and Michio Kanekiyo. The most prolific journals included The Journal of Alzheimer's Disease, Alzheimer's and Dementia, and Ageing Research Reviews. The most cited article was "Lecanemab in Early Alzheimer's Disease," by Van Dyck et al., published in The New England Journal of Medicine in 2023, which has accrued 172 citations. The 10 most frequently occurring keywords were Alzheimer's disease, lecanemab, dementia, aducanumab, amyloid-beta, immunotherapy, tau, a-beta, mouse model, and donanemab. Text mining revealed that drugs, anatomical structures, chemical molecules, genes, diseases, and procedures were significantly associated with both AD and lecanemab.

CONCLUSION:

The bibliometric and text mining analysis revealed trends in research investigating the correlation between lecanemab and AD. It analyzed the cooperation among countries, regions, and authors, highlighting recent research hotspots. These data offer objective insights for scientific research and clinical practice on lecanemab and AD. These findings provide a roadmap for prioritizing clinical trials, optimizing drug development strategies, and addressing knowledge gaps in amyloid-targeted therapies.

580

News (Medical) associated with Donanemab-AZBT

18 Nov 2025

·pharma.economictimes.indiatimes.com

Eli Lilly gets CDSCO nod for Alzheimer's drug Donanemab

New Delhi: US pharma major, Eli Lilly has secured CDSCO nod for its Alzheimer's drug Donanemab . The therapy is approved for adults with early symptomatic stages, particularly individuals with mild cognitive impairment (MCI) and those in the mild dementia stage of AD, with confirmed amyloid pathology. Before India, the therapy had secured marketing approval from the US FDA in 2024 and later in Japan and China as well. Donanemab , marketed under the brand name Kisunla, had initially faced reservations in Europe due to its limited efficacy in select patient group and its ability to ‘only delay the risk of serious adverse events’ such as brain swelling and bleeding. However, in July this year, the European Medicines Agency granted its approval following a re-examination bid from Lilly. Lilly’s drug is a disease modifying therapy that helps the body remove excessive buildup of amyloid plaques – a type of protein and slows the cognitive and functional decline. “The approval of Donanemab marks a significant milestone in our mission to address the urgent needs of people living with Alzheimer’s disease in India,” said Winselow Tucker, president and general manager, Lilly India. By Online Bureau ,

Drug Approval

14 Nov 2025

·www.globenewswire.com

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

Nov. 13, 2025 -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START’ Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesine (CT1812) in participants with mild cognitive impairment (MCI) or early Alzheimer’s disease. Topline results are expected after all participants have completed 18 months of treatment. “Our clinical operations teams drove impressive enrollment numbers this year based on strong interest from patients and investigators,” stated Lisa Ricciardi, Cognition’s president and CEO. “During the first half of 2025, we made presentations of our Phase 2 results in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies at international conferences and to the START investigators. The interest generated among investigators contributed to the strong enrollment figures, with approximately 50% of the entire study population enrolled during the last six months. We would like to thank our partners at ACTC and our investigators for their commitment, which led to this impressive accomplishment.” The START study was initiated shortly after Leqembi was granted accelerated approval in the US. Cognition and ACTC made the decision to allow people on stable background therapy with an approved monoclonal antibody therapy to participate. Approximately 15% of participants randomized into START were also receiving infusions of either Leqembi (lecanemab) or Kisunla (donanemab). Dr. Ryan O'Dell, MD, PhD, assistant professor of psychiatry at the Yale Alzheimer's Disease Research Unit and an investigator in the START study, added, “It’s an exciting time to be involved in Alzheimer’s disease research. With two approved anti-amyloid antibodies, many of our patients finally have new treatment options. But these disease-modifying therapies are only appropriate for some patients, leaving many with MCI and mild dementia due to Alzheimer’s disease, and the entire spectrum of people with more severe disease, without access to these novel treatments. The START study was a unique opportunity to investigate an experimental oral drug with a mechanism that is unlike that of the currently approved immunotherapeutics, with the potential to treat a broader segment of the Alzheimer’s patient community. And the prospect of combination therapy is particularly exciting for those patients receiving background Leqembi or Kisunla infusions as part of their clinical care.” “We expect zervimesine’s oral dosing and safety profile, with no increased risk of ARIA or need for serial imaging, to reduce the burden on patients and healthcare providers,” concluded Anthony O. Caggiano, Cognition’s chief medical officer. “We believe zervimesine has the potential to be an important part of the Alzheimer’s disease treatment arsenal for patients with early, mild and moderate Alzheimer’s disease.” The START Study (NCT05531656) is designed to measure the efficacy and tolerability of once-daily oral zervimesine in individuals with mild cognitive impairment (MCI) or early Alzheimer’s disease who have elevated Aβ as measured by PET or CSF. Participants are randomized to receive zervimesine or placebo for 18 months. The study will measure cognition and executive function using validated tools including the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and ADAS-Cog rating scales. Biomarkers and safety findings will also be assessed. The START Study is supported by an $81 million grant from the National Institute of Aging (NIA) at the National Institutes of Health (R01AG065248). The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC), an NIA-funded (grant number U24AG057437) clinical trial network of 35 leading academic sites with expertise in clinical trials in Alzheimer’s disease. Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB. Zervimesine has been generally well tolerated in clinical studies to date. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START Study (NCT05531656) in early Alzheimer’s disease is ongoing. We believe zervimesine can regulate pathways that are impaired in these diseases through its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. The content above comes from the network. if any infringement, please contact us to modify.

Immunotherapy

13 Nov 2025

·www.prnewswire.com

Century Health and Memory Treatment Centers Partner to Unlock Real-World Insights on Alzheimer's Disease Care Using AI

New treatments for Alzheimer's disease are transforming care for more than 7 million people in the US Memory Treatment Centers is at the forefront of caring for patients with memory loss and administering anti-amyloid therapies, building one of the most comprehensive real-world datasets on treatment outcomes Century Health's AI model transforms this complex data, spanning cognitive scores, biomarkers, genetics, and imaging, into evidence to guide treatment and research NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Century Health, a pioneer in applying AI to real-world data to accelerate research and advance therapeutics, and Memory Treatment Centers, a national leader in neurocognitive disease care, today announced a partnership to transform unstructured clinical data into research-grade real-world evidence. This enables rapid understanding of disease progression and how novel therapies for Alzheimer's disease perform outside clinical trials. The Century Health Abstraction and Retrieval Model (CHARM) will extract and standardize key variables, such as treatment response, cognitive assessments, genetic risk factors like Apolipoprotein E (APOE), and imaging findings like amyloid-related imaging abnormalities (ARIA). Century Health specializes in extracting clinical insights from unstructured clinical notes and imaging data, reducing the need for costly new data collection. These structured, de-identified data enable analysis of treatment effectiveness and safety across diverse patient populations, supporting hypothesis generation and post-market research at scale. All analyses use de-identified data and adhere to strict HIPAA-compliant privacy safeguards. The resulting high-quality, compliant datasets can be used by clinicians, investigators, and pharmaceutical partners to assess treatment effectiveness, real-world safety, and value across populations. This evidence helps bridge real-world outcomes to research and access decisions, enabling continuous learning about safety, effectiveness, and patient impact across the treatment lifecycle. "Memory Treatment Centers is dedicated to advancing care for Alzheimer's disease and other forms of dementia," said Dr. Bobby Mannel, neurologist and co-founder of Memory Treatment Centers. "By collaborating with Century Health, we can analyze how new treatments perform in real-world settings and learn how to optimize care for every patient we serve." Memory Treatment Centers has been at the forefront of Alzheimer's treatment. The group was the first in the US to administer donanemab and lecanemab, FDA-approved therapies shown to slow early Alzheimer's progression by targeting amyloid plaques. Memory Treatment Centers' comprehensive approach to diagnosis and care has established it as one of the nation's leading centers for early adoption and real-world monitoring of disease-modifying treatments. "Practices serving the most affected populations often hold uniquely powerful data to inform clinical and translational research," said Vish Srivastava, Co-Founder & CEO at Century Health. "By partnering with one of the largest and most advanced Alzheimer's and dementia practices in the country, we can help translate everyday care data into insights that directly shape future treatments." Research into Alzheimer's disease is critical, as it is a progressive disease with no cure. More than 7 million people in the US live with the disease today, and that number is expected to double by 2060. With Florida among the states with the highest populations of Alzheimer's patients in the country, the partnership highlights the importance of scalable, real-world research in community settings to advance understanding and improve outcomes. About Memory Treatment Centers At Memory Treatment Centers, we are leaders in innovative treatments and advancing the level and effectiveness of memory diagnosing, treatment, and monitoring. Committed to providing hope and relief to individuals struggling with various forms of cognitive impairment, including Alzheimer's Disease, our goal is to help patients achieve better health and a higher quality of life. We actively pursue new treatment opportunities and partnerships to enhance memory care and expand patient access to treatment. Additionally, we strive to help and educate individuals and caregivers, ensuring they have the support and knowledge needed on their journey to improved well-being. For more information, visit memorytreatmentcenters.com About Century Health Century Health is a health technology company transforming how real-world evidence is generated from clinical data. With its AI-powered platform, Century Health unlocks rich, high-quality datasets from fragmented and siloed clinical information to fuel groundbreaking research and industry collaborations. By automating data curation and enrichment, the platform eliminates manual data entry while upholding the highest standards of patient privacy. Partnering with leading academic institutions, healthcare providers, and life sciences organizations, Century Health accelerates breakthrough treatments with the power of AI. For more information, visit . Media Contact Rob Mazzini Mazzini Public Relations [email protected] SOURCE Century Health 21% more press release views with Request a Demo

100 Deals associated with Donanemab-AZBT

External Link

KEGG	Wiki	ATC	Drug Bank
D11500	Donanemab-AZBT	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Alzheimer Disease	United States	Eli Lilly & Co.	02 Jul 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psychotic Disorders	NDA/BLA	Canada	Eli Lilly Canada, Inc.	-
Neurocognitive Disorders	Phase 3	China	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Argentina	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Australia	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Poland	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	South Korea	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Spain	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Taiwan Province	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	United Kingdom	Eli Lilly & Co.	10 Oct 2022
Cognitive Dysfunction	Phase 2	United States	Eli Lilly & Co.	23 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05738486 (TRAILBLAZER-ALZ 6, CTgov)	Phase 3	Alzheimer Disease \| Neurocognitive Disorders	1,175	Placebo+Donanemab (1400 mg Donanemab - Standard Regimen)	hpdngjfszj = tpgtjkhnsw xzdcvzsywh (xgjnlnwavq, jqjovferob - nkrngvkfgi) View more	-	14 Nov 2025
				Placebo+Donanemab (1400 mg Donanemab - Dose Skipping)	hpdngjfszj = imbswuboxb xzdcvzsywh (xgjnlnwavq, nttgvelaro - htdmcufpzb) View more
NCT04437511 (TRAILBLAZER-ALZ 2, PRNewswire) Manual	Phase 3	Alzheimer Disease	-	Kisunla	itsnshhbbv(lwrlsibdik): Difference = -0.6 View more	Positive	30 Jul 2025
				Neuroimaging Initiative (untreated external cohort)
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ and ALZ 2, Pubmed \| JAMA Neurol)	Not Applicable	Alzheimer Disease APOE ε4 allele number \| amyloid levels	3,030	Donanemab	assdcmquzi(detujaergu) = nzojgjvtjx gtbggxrerd (ivwapuevem ) View more	Positive	01 May 2025
				Placebo	assdcmquzi(detujaergu) = gazpihwpsx gtbggxrerd (ivwapuevem ) View more
NCT05108922 (TRAILBLAZER-ALZ 4, Pubmed \| Alzheimers Dement)	Phase 3	Alzheimer Disease amyloid plaque clearance	148	Donanemab	ayhgqtsmrg(ewafiejuoc) = ewafajncau wazjurdkyx (gzqdczlspx ) View more	Positive	01 May 2025
				Aducanumab	ayhgqtsmrg(ewafiejuoc) = awryjneduk wazjurdkyx (gzqdczlspx ) View more
NCT05738486 (TRAILBLAZER-ALZ 6, Company_Website 1 \| Company_Website 2) Manual	Phase 3	Alzheimer Disease	843	received two vials (700 mg) of donanemab for the first three infusions, then four vials (1400 mg) thereafterdonanemab for the first three infusions, then four vials (1400 mg) thereafter (Standard Dosing Regimen)	owhfyohktp(mzopphwgfm) = mhilbnjkpz smdzfgvyni (tomqzgnybp ) View more	Positive	29 Oct 2024
				received 1 vial (350 mg) of donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion,donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion, and four vials (1400 mg) per infusion thereafter (Modified Titration)	owhfyohktp(mzopphwgfm) = ggtiyujxjn smdzfgvyni (tomqzgnybp ) View more
NCT05567159 (CTgov)	Phase 1	-	42	Donanemab	hxtlejvhpv(ukjwzilkxr) = kaisojoqoc nkrkbigagc (gmzqktmogu, 23) View more	-	04 Oct 2024
NCT01837641 (CTgov)	Phase 1	Alzheimer Disease \| Cognitive Dysfunction \| Mild cognitive disorder	63	Placebo (Placebo IV)	cbryqwhkcv = bzcfvvfukq ynldvjbmuy (umimqyqveu, hnivlafpjm - bykexauibw) View more	-	04 Oct 2024
				LY3002813 (0.1 mg/kg / 0.3 mg/kg LY3002813 IV)	cbryqwhkcv = gmndliuxjc ynldvjbmuy (umimqyqveu, ftxxznoxcm - xnirodbdjr) View more
NCT05533411 (CTgov)	Phase 1	-	36	Placebo (Placebo)	bcyxeskakm = mipeocgomq jjiljgnufd (ygdmgyrhbd, ajoqlblkqy - kdbwlhtbuo) View more	-	04 Oct 2024
				Donanemab (700 mg Donanemab)	bcyxeskakm = gjpihqrhuf jjiljgnufd (ygdmgyrhbd, ibvpgdiynr - phzywttzlq) View more
NCT04437511 (FDA_CDER) Manual	Phase 3	Alzheimer Disease	1,736	KISUNLA	znuqktmdss(xrnssaqcsk): Difference = 2.92, P-Value = <0.0001 View more	Positive	02 Jul 2024
				Placebo
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ \| TRAILBLAZER-ALZ2, AAN2024)	Phase 2/3	number of microhemorrhages \| cortical superficial siderosis \| mean arterial pressure ... View more	2,031	Donanemab	axtawjubhg(qgnhghltss) = uvxrklhpkf fhpcodzjox (luzubedfzu )	Positive	09 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis